Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Reflected in the sales data, Eli Lilly's financial report shows that tirzepatide, with its two indications of blood - sugar control (Mounjaro) and weight loss (Zepbound), achieved a total revenue of $5 billion in Q1 2025, accounting for approximately 39% of the company's revenue during the same period, and its year - on - year growth rate exceeded 100%
It changes the conditions that make weight gain easier and weight loss harder
Several case reports have documented individual patients with lipedema who experienced symptomatic improvement and some reduction in limb circumference while taking incretin-based medications, particularly semaglutide
As an investigational peptide with extensive clinical trial data, it offers researchers a well-characterized tool for studying amylin receptor biology [18]
